Monthly News Roundup - June 2018
First Cannabis-Based Drug Epidiolex Approved for Childhood Seizures
In June, the U.S. Food and Drug Administration (FDA) approved GW Pharmaceuticals' Epidiolex (cannabidiol) [CBD], an oral solution for patients two years and older to treat seizures linked with two rare and severe forms of epilepsy -- Lennox-Gastaut syndrome and Dravet syndrome. Epidiolex is the first FDA-approved drug from a marijuana-based substance. Unlike tetrahydrocannabinol (THC), CBD does not cause intoxication or a 'high'. In pivotal studies Epidiolex was shown to be effective in reducing the frequency of seizures when compared with placebo. Common side effects include sleepiness, elevated liver enzymes, and decreased appetite, among others.
https://www.drugs.com/news/monthly-news-roundup-june-2018-75351.html
